Arguably, the most prominent ‘sleeper’ disease that contributes to 1 in every 2 to 3 hospital deaths is sepsis.1 Fueled by lipopolysaccharide (LPS)2— referred to clinically as endotoxin when it activates an immune response3— LPS was primarily viewed as an acute trigger of sepsis and systemic inflammatory response syndrome. Today, a much broader picture is emerging. LPS may be one of the most important chronic innate immune activators driving cardiometabolic disease, neuroinflammation, cancer, immune dysregulation, accelerated aging, and many of the chronic inflammatory ‘mystery illnesses’ seen in clinical practice.
For integrative and functional health practitioners, lipopolysaccharide (LPS) may be best understood not only as an acute sepsis trigger, but also as a pattern-recognition stressor that can help explain chronic inflammatory burden, cardiometabolic risk, immune dysregulation, and shortened healthspan. LPS acts a ‘stealth disruptor’ of healthy lifespan, driving intestinal permeability, increasing circulating endotoxins, and fueling inflammatory signaling—with systemic impacts that often manifest in a myriad of mystery symptoms.
The conventional understanding has been that LPS exerts its inflammatory effects primarily outside the cell by binding Toll-like receptor 4 (TLR4), activating NF-κB signaling, and increasing inflammatory cytokines such as TNF-α, IL-6, and IL-1β. But a groundbreaking 2024 paper published in Inflammation adds a critically important new layer to the story. The researchers demonstrated that galectin-3 may actively facilitate the internalization of endotoxin into cells, where LPS can trigger an entirely different and potentially far more destructive inflammatory cascade. Importantly, inhibition of galectin-3 with the researched form of Modified Citrus Pectin (MCP), significantly attenuated endotoxin-induced pyroptosis (a highly inflammatory form of programmed cell death primarily triggered by infections or danger signals), reduced inflammatory injury, improved renal pathology, and improved survival in experimental sepsis models. This suggests that interrupting intracellular endotoxin trafficking may represent an important next-generation therapeutic strategy in sepsis and endotoxin-driven inflammatory disease.4
This is a major conceptual shift.
The danger of endotoxin may not be limited to what it does in the bloodstream, or when it gets into organs (brain, liver, kidneys, muscles,…). The greater danger may occur once endotoxin gains access inside the cells of the brain, liver, muscles, kidneys….
The study demonstrated that galectin-3 drives LPS trafficking into early endosomes and lysosomes in both macrophages and renal tubular epithelial cells through RAGE-dependent and RAGE-independent mechanisms. Once endotoxin escaped into the cytoplasm, it activated the noncanonical inflammasome through caspase-4/11 signaling, triggering pyroptosis—via IL-1β and IL-18 release and significant tissue injury.4
In simple terms, galectin-3 appears to function not only as a marker of inflammation and fibrosis, but also as a facilitator of intracellular endotoxin trafficking.
This distinction may help explain why attempts to block TLR4 alone (whether pharmaceutically or neutraceutically) have not consistently solved endotoxin-driven inflammatory conditions. Endotoxin signaling is not occurring exclusively at the cell surface. LPS may also be entering cells through outer membrane vesicles (OMVs), lipid raft transcytosis pathways, caveolae-mediated transport systems, and galectin-3-associated intracellular trafficking mechanisms. Once inside the cytoplasm, endotoxin activates a deeper intracellular danger response involving inflammasomes, caspase activation, gasdermin D pore formation, pyroptosis, and amplification of chronic inflammatory signaling. Once again, major conceptual shift.
Galectin-3 may sit at the ‘headgates’ of chronic low-grade systemic inflammation. Increasing evidence suggests it functions not merely as a downstream marker of disease, but as an upstream amplifier of inflammatory signaling within the cell activating fibrosis, immune dysregulation, and tissue degeneration. Galectin-3 is expressed throughout the body—including the nucleus, cytoplasm, mitochondria, cell surface, and extracellular space—and is readily secreted into serum and urine during inflammatory activation and tissue injury. Elevated galectin-3 has now been associated with cardiovascular disease, chronic kidney disease, autoimmune disease, neurodegeneration, fibrosis, metabolic dysfunction, and tumor biology—and importantly, appears to rise very early in the disease process, often before overt clinical pathology is recognized. In many ways, galectin-3 may represent one of the body’s earliest measurable signals that chronic innate immune activation and degenerative inflammatory processes are underway.
For clinicians, this creates a much broader framework for understanding chronic disease progression.
The body has multiple layered defense systems designed to neutralize endotoxin before it reaches systemic circulation. Secretory IgA helps contain microbial products at mucosal surfaces reducing absorption, while intestinal alkaline phosphatase detoxifies LPS by dephosphorylating lipid A, reducing its inflammatory potential. Lipoproteins—including HDL, LDL, VLDL, and chylomicrons—then function as innate immune buffering systems that bind and transport endotoxin for hepatic clearance and biliary excretion.
However, when microbial burden, dysbiosis, periodontal disease, environmental toxic burden, ultra-processed foods, alcohol exposure, stress physiology, PM2.5 exposure, or chronic barrier dysfunction overwhelm these protective systems, persistent low-grade endotoxemia may develop. In this environment, galectin-3 expression rises as part of the innate immune response. Ironically, the same galectin-3 system designed to help protect against microbial invasion may now facilitate intracellular endotoxin trafficking and amplify inflammatory injury.
This may represent one of the core mechanisms underlying inflammaging.
Over time, chronic endotoxin signaling contributes to endothelial activation, vascular permeability, mitochondrial dysfunction, insulin resistance, fibrosis, neuroinflammation, and progressive tissue degeneration. Importantly, endotoxin vulnerability is not limited to the gut or vascular system. Adipose tissue, skeletal muscle, periodontal tissue, kidney, liver, brain, placenta, and many other tissues appear capable of responding to or internalizing endotoxin signaling under chronic inflammatory conditions.
This newer understanding also reframes hsCRP and inflammatory biomarkers. IL-6—one of the primary cytokines induced by endotoxin signaling—is a major driver of hepatic CRP production. Thus, elevated hsCRP may not simply reflect vague “inflammation,” but may represent a downstream hepatic acute-phase signal of chronic innate immune activation, including endotoxin-related inflammatory signaling.
Importantly, galectin-3 may provide clinicians with a much earlier warning signal than conventional inflammatory biomarkers. Multiple studies now suggest galectin-3 elevation can precede overt tissue degeneration and clinical disease manifestation. Experimental models demonstrate galectin-3 upregulation before overt heart failure, before neurologic impairment in Huntington’s disease models, during early demyelination, and in early neoplastic transformation. In many ways, galectin-3 may be functioning as an ‘early smoke alarm’ for chronic inflammatory degeneration long before accumulative catastrophic tissue damage becomes clinically obvious.
This is one reason Modified Citrus Pectin (MCP) has generated increasing attention in both the scientific and integrative medicine communities. MCP is the most extensively researched natural galectin-3 blocker currently available, with published studies demonstrating effects on fibrosis, immune modulation, tumor biology, inflammatory signaling, and metastatic progression.
The exciting aspect of the Inflammation study is that the researched form of MCP attenuated many of these endotoxin-driven effects.4 MCP reduced LPS-induced pyroptosis, lowered IL-1β and IL-18 signaling, improved kidney injury pathology, and improved survival in experimental models. Earlier research has also demonstrated that modified citrus pectin compounds can suppress endotoxin-induced inflammatory signaling through inhibition of JNK, ERK, p38, AP-1, and NF-κB activation pathways.5
The oncology literature surrounding galectin-3 is particularly compelling. Galectin-3 appears to facilitate tumor adhesion, angiogenesis, immune evasion, metastatic spread, and extracellular matrix scaffolding. In prostate cancer, MCP has demonstrated encouraging clinical findings in patients with biochemical recurrence following surgery or radiation. Interim Phase IIb trial data presented at the ASCO Genitourinary Cancer Conference showed that approximately 79% of men with recurrent non-metastatic prostate cancer experienced slowing or stabilization of PSA progression dynamics while taking MCP. Earlier studies similarly demonstrated prolongation of PSA doubling time in men with recurrent prostate cancer.
From a systems-biology perspective, this becomes extremely interesting.
The same galectin-3 biology involved in fibrosis, immune dysregulation, endothelial dysfunction, and chronic inflammatory degeneration may also contribute to tumor progression and metastatic behavior. Galectin-3 is increasingly understood as a biologic ‘amplifier’ molecule—facilitating inflammatory signaling, cellular adhesion, extracellular matrix interactions, immune escape, and tissue remodeling across multiple chronic disease states.
From an integrative clinical perspective, MCP may therefore represent an important adjunctive strategy for interrupting the feed-forward inflammatory axis between endotoxin and galectin-3. This does not mean MCP is a treatment for sepsis, kidney injury, cardiovascular disease, cancer, or any endotoxin-driven disease state. However, it is increasingly recognized as a clinically relevant galectin-3 modulator capable of supporting systemic inflammatory balance across multiple organ systems.
This becomes especially important if galectin-3 is functioning not simply as a passive biomarker, but as an active participant in disease progression. The literature increasingly supports galectin-3 as both a mediator and marker of fibrosis, immune activation, inflammasome signaling, neuroinflammation, vascular injury, tissue remodeling, and tumor biology. Clinically, this raises the possibility that reducing galectin-3 activity, ‘throttling back’ the flow of inflammatory cytokine production at ‘the headgates’ of intracellular cytokine activity may help dampen the amplification loop between endotoxin trafficking and chronic inflammatory injury.
Practically, clinicians can now begin thinking beyond the simplistic concept of ‘leaky gut’ – albeit a recognized primary pathway of LPS entry into systemic circulation. Endotoxin biology is increasingly understood as a complex trafficking network involving mucosal immunity, lipid transport systems, outer membrane vesicles, intracellular trafficking pathways, inflammasome signaling, and pyroptotic tissue injury.
The clinical implications are profound. Given that 9 out of the top 10 causes of death are chronic inflammatory diseases,6 efforts to bind and modulate galectin-3 activity, such as MCP, may help reduce both extracellular inflammatory signaling and the intracellular amplification of cytokine cascades triggered by endotoxin exposure, tissue injury, and chronic immune activation. Clinically, this suggests a potential ‘dampening effect’ on the chronic low-grade inflammatory fire that underlies vascular dysfunction, fibrosis, insulin resistance, neuroinflammation, neurodegeneration, and accelerated biological aging.
Strategic interventions aimed at reducing endotoxin burden, improving oral and gut microbial ecology, supporting secretory IgA and mucosal integrity, optimizing dietary fiber diversity, reducing ultra-processed food exposure, improving HDL functionality, and modulating galectin-3 activity may collectively help interrupt chronic innate immune activation and support healthier aging trajectories.
In many ways, chronic disease may ultimately represent progressive failure of the body’s layered endotoxin defense systems. Perhaps the next frontier in chronic disease is not simply identifying inflammation after tissue damage has occurred, but understanding the biologic ‘traffic controllers’ that determine where inflammatory signals go, how deeply they penetrate into the cell, and whether they ignite self-perpetuating cycles of degeneration. The emerging science surrounding endotoxin trafficking, galectin-3 biology, inflammasome activation, and pyroptosis suggests we may only be beginning to appreciate the true complexity of chronic innate immune activation and its potential eventual progression into sepsis. Importantly, the growing literature surrounding the researched form of Modified Citrus Pectin suggests that modulation of galectin-3 activity may help attenuate many of these downstream consequences—including fibrosis, inflammatory cytokine amplification, endotoxin-induced tissue injury, tumor progression, and immune dysregulation.
Related Webinar:
Sources:
- Hospital deaths in patients with sepsis from 2 independent cohorts. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ. JAMA. 2014 Jul 2;312(1):90-2
- Lipopolysaccharide (LPS)-induced inflammation in RAW264.7 cells is inhibited by microRNA-494-3p via targeting lipoprotein-associated phospholipase A2. Yan W, Yan Y, Luo X, Dong Y, Liang G, Miao H, Huang Z, Jiang H. Eur J Trauma Emerg Surg. 2024 Dec;50(6):3289-3298
- Role of Endogenous Lipopolysaccharides in Neurological Disorders.Kalyan M, Tousif AH, Sonali S, Vichitra C, Sunanda T, Praveenraj SS, Ray B, Gorantla VR, Rungratanawanich W, Mahalakshmi AM, Qoronfleh MW, Monaghan TM, Song BJ, Essa MM, Chidambaram Cells. 2022 Dec 14;11(24):4038
- Wang F, Ye J, Zhu W, Ge R, Hu C, Qian Y, Li Y, Peng Z. Galectin-3 Mediates Endotoxin Internalization and Caspase-4/11 Activation in Tubular Epithelials and Macrophages During Sepsis and Sepsis-Associated Acute Kidney Injury. Inflammation. 2024 Feb;47(1):454-468. doi: 10.1007/s10753-023-01928-w. Epub 2023 Nov 18. PMID: 37979076. (PubMed)
- Chen CH, Sheu MT, Chen TF, Wang YC, Hou SC, Liu DZ, Chung TC, Liang YC. Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS signaling pathways. Biochem Pharmacol. 2006;72(8):1001-1009. doi:10.1016/j.bcp.2006.07.007 (PubMed)
- https://www.cdc.gov/nchs/data/databriefs/db548.pdf accessed 5-11-26
